Le Corfec E, Le Pont F, Tuckwell H C, Rouzioux C, Costagliola D
Epidemiology and Science of Information, INSERM U444, Hôpital Necker, Paris, France.
Transfusion. 1999 Oct;39(10):1141-4. doi: 10.1046/j.1537-2995.1999.39101141.x.
This study was designed to evaluate the potential yield of introducing nucleic acid amplification testing (NAT) in blood donation, according to the detection threshold and the pool size.
A mathematical model of early HIV-1 population dynamics in blood has been developed and is used to predict the window period for NAT, according to the detection threshold and the pool size. The corresponding number of undetected, infected blood donations and the residual risk are estimated by using a previously published simulation model for the United States (9.96 million blood donations from regular donors, and an observed rate of HIV antibody-positive blood donations of 3.18/100,000) and for France (2.32 million blood donations, and a rate of antibody-positive donations of 0.9/100,000).
The average window period from infection predicted by the mathematical model for NAT ranges from 8.4 to 15.6 days, according to the detection threshold and the pool size. The maximum yield of adding NAT to the current antibody tests is estimated at 14 donations for the United States and 2 for France. The maximum yield of adding NAT to the newly developed combined HIV antibody and p24 antigen tests is 7 donations for the United States and 1 for France.
NAT at blood donation could reduce the HIV-1 window period to a minimal value of 8 days without pooling the blood samples, but the yield of NAT would be close to that of combined HIV antibody and p24 antigen tests for high values of the detection threshold and the pool size.
本研究旨在根据检测阈值和混合样本量评估在献血中引入核酸扩增检测(NAT)的潜在收益。
已建立血液中早期HIV-1群体动态的数学模型,并用于根据检测阈值和混合样本量预测NAT的窗口期。使用先前发表的针对美国(来自定期献血者的996万次献血,观察到的HIV抗体阳性献血率为3.18/100,000)和法国(232万次献血,抗体阳性献血率为0.9/100,000)的模拟模型估计未检测到的感染献血数量及残余风险。
根据检测阈值和混合样本量,数学模型预测的NAT感染后平均窗口期为8.4至15.6天。在美国,将NAT添加到当前抗体检测中的最大收益估计为14次献血,在法国为2次献血。将NAT添加到新开发的HIV抗体和p24抗原联合检测中的最大收益,在美国为7次献血,在法国为1次献血。
献血时进行NAT可将HIV-1窗口期缩短至最短8天,无需混合血样,但对于高检测阈值和混合样本量,NAT的收益将接近HIV抗体和p24抗原联合检测的收益。